logo
The 5 Most Interesting Analyst Questions From Watts Water Technologies's Q1 Earnings Call

The 5 Most Interesting Analyst Questions From Watts Water Technologies's Q1 Earnings Call

Yahoo2 days ago
Watts Water's first quarter results were met with a positive market reaction, as the company outperformed Wall Street's revenue and profitability expectations despite a year-over-year sales decline. Management cited the benefit of its regionally focused manufacturing strategy and strong execution in the Americas, with CEO Bob Pagano noting, 'Our primary strategy has been to make products in the regions for the region.' While organic sales slipped due to fewer shipping days and ongoing weakness in Europe, Watts offset these headwinds with disciplined cost control and contributions from recent acquisitions, particularly in the U.S. segment.
Is now the time to buy WTS? Find out in our full research report (it's free).
Revenue: $558 million vs analyst estimates of $547.8 million (2.3% year-on-year decline, 1.9% beat)
Adjusted EPS: $2.37 vs analyst estimates of $2.13 (11.3% beat)
Adjusted EBITDA: $119.8 million vs analyst estimates of $110.1 million (21.5% margin, 8.8% beat)
Operating Margin: 15.7%, down from 16.9% in the same quarter last year
Organic Revenue fell 2.1% year on year (6.4% in the same quarter last year)
Market Capitalization: $8.52 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Nathan Jones (Stifel) asked about gaining market share due to Watts' U.S.-centered manufacturing advantage. CEO Bob Pagano explained that while the company benefits from its regional focus, it aims to 'get our fair share' and will monitor how tariffs affect competitive dynamics throughout the year.
Mike Halloran (RW Baird) questioned whether management's cautious second-half outlook reflects real-time softness or just prudence. Pagano confirmed it is primarily caution due to macroeconomic uncertainty, rather than observed demand deterioration so far.
Jeff Hammond (KeyBanc) inquired about prebuying behavior ahead of price increases and how Watts is controlling this effect. Pagano acknowledged some customer prebuying, estimated at $5 million in the first quarter, and described measures to limit excessive orders based on historical purchasing patterns.
Ryan Connors (Northcoast Research) explored the extent to which raw material shortages (like bismuth) are driving price increases versus tariffs. Management replied that tariffs are the main factor; raw material constraints are being managed with adequate inventory levels.
Andrew Krill (Deutsche Bank) asked about capacity to expand U.S. manufacturing and the need for incremental investment. Pagano said current facilities can add shifts without significant capex, as most are not running at full utilization.
In the coming quarters, the StockStory team will monitor (1) Watts' ability to maintain margin resilience as tariffs and pricing actions flow through, (2) signs of demand normalization or further weakness in Europe, particularly in construction and heat pump channels, and (3) progress on integration and synergy capture from recent acquisitions like I-CON. Updates on any trade policy changes and their impact on supply chain strategy will also be closely watched.
Watts Water Technologies currently trades at $255.29, up from $211.59 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Yahoo

time21 minutes ago

  • Yahoo

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Yahoo

time21 minutes ago

  • Yahoo

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Yahoo

time25 minutes ago

  • Yahoo

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store